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Abstract 
 
This chapter considers the prevalence of and motivations for use of synthetic cathinones. As part of 
the scene-setting, the availability, legal status, numbers of cathinones, number and quantities 
confiscated are reviewed. This leads to the first substantive section of the chapter - an epidemiological 
investigation of the nature and extent of what is known about the use of these molecules. The second 
major section is more qualitative in its approach to understanding motivations for the use of any drug, 
Novel Psychoactive Substances (NPS), and then natural cathinones and synthetic cathinones. An 
examination is conducted of how cathinones may be compared to other stimulants and why particular 
cathinones may be preferred to others. The converse situation is then examined, what might be the 
motivations and reasons for ceasing to take cathinones and why this may not be rational decision. A 
brief examination of the consequences of ceasing versus continued use is presented. As it is very 
likely that further synthetic cathinones will continue to emerge, it is important to gain a much fuller 
insight into what motivates or causes individuals to use or cease using these molecules, so that 
communities and societies can respond in appropriate ways to the varying challenges that face them 
and their citizens.   
 
 
 
[Word count: 206] 
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9.1: Introduction and Background 
 
Despite the continuing increase in the emergence of Novel Psychoactive Substances (NPS), a core 
group of over 80 NPS have become established as attractive recreational drugs, supplementing 
traditional drugs of abuse and becoming part of the repertoire of substances available for consumption 
(UNODC, 2017a; Moore et al., 2013). This group has been reported every year from 2009 to 2016, 
including mephedrone and derivatives. In Central Asia, this group accounts for 42% of all new NPS 
notifications in 2013-6 compared to 16% of NPS notified from the Near and Middle East since 2008 
(UNODC, 2017b). It is important, therefore, to understand the prevalence and motivations for use of 
the largest NPS groups, including synthetic cathinones (EMCDDA, 2016a; EMCDDA, 2017; UNODC, 
2016a), in order to appropriately understand the nature and extent of the problem. This will facilitate 
the design of better-informed data collection models, as well as the delivery of appropriately tailored 
harm-reduction techniques and initiatives. 
 
Estimating demand for and supply of psychoactive substances is problematic even for traditional drugs 
of abuse, let alone for NPS (Corkery et al., in press). For example, the number of NPS confiscations or 
the amounts of NPS seized by law enforcement agencies only reflect operational priorities by such 
organisations. Furthermore, only very inaccurate estimates can be made as to what proportion of the 
total supply of specific substances is accounted for by such law enforcement agency interdictions. On 
the demand side, very little is known about the nature of NPS consumption, especially with regard to 
typical doses taken to achieve particular effects, accuracy of dose measurement, frequency of dosing, 
need to redose, tolerance, duration of effects, length of half-life, metabolism, toxic and fatal levels, etc.  
 
However, international agencies such as the United Nations Office for Drugs and Crime (UNODC) and 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) have work programmes 
aiming to enhance the development of more timely and robust techniques to not only monitor the 
current situation with regard to the NPS phenomenon but also predict future evolutions. In the 
meantime, we have to deal with the limitations and vagaries of the established monitoring systems and 
the challenges which face them (Palamar et al., 2015; UNODC, 2017a). Whilst patterns can be 
observed in the number and type of NPS being reported to such international agencies, there are 
limitations in terms of the timeliness of detection, accurate identification and submission of reports by 
law enforcement, forensic and toxicological services. Furthermore, whilst we may have a good 
estimate through these indicators of the number of NPS in circulation, the actual numbers that have 
been created and held ready for sale are likely to be higher.  
 
It is very challenging to accurately estimate the prevalence of specific NPS classes because most of 
the surveys conducted focus either on NPS as a whole or on specific NPS, although some progress 
has been made in recent years in improving survey instruments and tools (UNODC, 2017a). Other 
technical issues include: self-reporting surveys, such as the Global Drug Survey (Winstock et al., 
2017) may not be representative of all users; there may be differences between respondents who 
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have internet access and chose to participate compared to those who lack such access or desire to 
take part (Ashrafioun et al., 2016). General household surveys which will not capture people living 
alone, in institutional settings (hospitals, penal establishments, student accommodation, sheltered 
housing, etc.) or those who are ‘homeless’ or ‘roofless’ resorting to ‘sofa-surfing’ – who often comprise 
individuals most at risk of using and/or dependent on psychoactive substances, including synthetic 
cathinones. It often takes a relatively long period to get specific questions on special topics included in 
regular surveys, such as the Crime Survey for England and Wales (Broadfield, 2017), so that by the 
time the survey is in the field the substances being asked about may have disappeared from the 
market. Palamar et al. (2017) argue that ‘gate’ questions, which adopt a ‘skip-logic’ approach in 
surveys such that “only a “yes” response to the use of specific drug class is followed by more 
extensive queries of drug use in that drug class”, may impact the accuracy of collected data via self-
reporting. Therefore, surveys on NPS use should explicitly include the NPS classes, the specific NPS 
within each class as well as the street names.   
 
NPS users often have little knowledge about what molecules they are actually consuming; they may 
only be aware of a brand name or a ‘street’ name, and almost certainly will not have had it analysed. 
That said, often products purchased as ‘research chemicals’ are indeed what they purport to be 
(Guirguis et al., 2017).  
 
In this chapter we focus on the second largest group of NPS – synthetic cathinones. As noted 
elsewhere in this book, these substances are synthetic derivatives of the natural amphetamine-like 
substances 9cathine and cathinone) present in the leaves and stalks of the khat plant (Catha edulis), 
which produce mild stimulant and other psychoactive effects (Corkery, 2016).  
 
 
9.2: Availability of synthetic cathinones 
 
Before taking a closer look at the information available about the extent of use of synthetic cathinones, 
we will briefly review the situation regarding their availability. In Europe, by the end of 2016, some 629 
NPS of all classes were being monitored by the EMCDDA, of which 66 were reported for the first time 
in 2016 (EMCDDA-Europol, 2017). By the end of 2016, 739 substances had been reported by 106 
countries and territories through the global Synthetics Monitoring: Analysis, Reporting and Trends 
(SMART) programme to the UNODC (2017a); the number of NPS reported increased from 126 to 450 
between 2009 and 2014.  
 
 
9.2.1: Legal status of cathinones 
 
Khat is regarded as “a particular NPS of concern” by the UNODC (2014). Although the plant itself is 
not under international control, at present, two of the principal psychoactive substances that are 
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present in it, cathine and cathinone are. This because in the early 1980s all amphetamine-like 
substances were placed group-wise under international control (ECCD, 1985). Cathinone was 
included in Schedule I of the UN Convention on Psychotropic Substances in 1988, and cathine was 
then included in Schedule III of this Convention. Cathinone and cathine are controlled substances 
under Class C of the UK Misuse of Drugs Act 1971 by virtue of Schedules 1 and 3 respectively of the 
Misuse of Drugs (Amendment) Regulations Act 1986. 
 
A number of persistent NPS have been brought under international control, among them several 
cathinones: α-pyrrolidinovalerophenone (α-PVP) was placed under international control in 2016; 3,4-
methylenedioxypyrovalerone (MDPV), mephedrone and methylone in 2015, all under Schedule II of 
the 1971 Convention on Psychotropic Substances (UNODC, 2017a). In March 2017, the Commission 
on Narcotic Drugs decided to add ethylone, pentedrone and 4-methylethcathinone (4-MEC) to the 
same Schedule. In the USA, MDPV, mephedrone and methylone come within the compass of 
Schedule I of the Controlled Substances Act 1970. 
 
At the EU level, mephedrone was submitted to control measures in EU Member States by the 
European Council’s decision of 2 December 2010 (2010/759/EU). Some cathinone derivatives are 
caught by drug control or equivalent legislation, for example: mephedrone (Belgium, Crotia, Denmark, 
Estonia, France, Germany, Ireland, Italy, Lithuania, Norway, Romania, and Sweden); methylone 
(Denmark, Ireland, Romania and Sweden); butylone (Denmark, Ireland, Norway, Romania, and 
Sweden); MDPV (Denmark, Ireland, Finland and Sweden); and flephedrone (Denmark, Ireland and 
Romania). Medicines’ legislation is used in Finland and the Netherlands to control mephedrone. In the 
UK context, several generations/classes of synthetic cathinones and derivatives have been dealt with 
by means of generic definitions under the 1971 Act as Class B drugs and under Schedule 1 of the 
Misuse of Drugs Regulations (2003, as amended).  
 
Some synthetic cathinones are licensed for medicinal use. For example, Bupropion (Zyban, 
Wellbutrin), primarily used as an antidepressant and smoking cessation aid, has been used 
recreationally (Vento et al., 2013). Pyrovalerone, developed in the late 1960s and structurally related 
to MDPV, has been used in the clinical treatment of chronic fatigue and lethargy due to its stimulant 
effects (Gardos and Cole, 1971), as well as an appetite suppressant and anorectic in countries such 
as France. However, it is not often prescribed these days because of issues with abuse and 
dependence (Deniker et al., 1975). The molecule is covered by Schedule IV of the 1971 UN 
Convention; it was controlled as a Class C drug under the Misuse of Drugs Act 1971 prior to the 
inclusion of other cathinones in April 2010.  
 
In the past, synthetic cathinones could be purchased through a range of legal retail outlets, including  
convenience stores, gas/petrol stations, ‘head’/’smart’ shops, ‘adult’ stores, etc. (Meyers et al., 2015).  
Over the last decade, the Internet has become a major nexus for information on, and a leading market 
place for the purchase of NPS in general, but also for this group of psychoactive molecules. In fact, the 
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anonymity of the Internet has often been proposed as a reason for the growth in use of synthetic 
cathinones. However, the imposition of so-called ‘blanket bans’ by national governments, e.g. the 
Republic of Ireland and the UK, has not only led to the closure of retail outlets such as ‘head’/’smart’ 
shops and an open source of NPS, but has driven the market for NPS to the clandestine street market 
alongside traditional drugs such as amphetamine, cannabis, cocaine and heroin (Shapiro and Daly, 
2017), as well as to the deeper recesses of the Internet. Wadsworth et al. (2017) report a possible shift 
of cathinone sales in the UK from the surface web to the deep web, following the coming into effect of 
the Psychoactive Substances Act 2016 on 26 May 2016. 
 
 
9.2.2: Number of synthetic cathinones 
 
At a global level, the UNODC reported that the number of synthetic cathinones identified/reported by 
member countries and territories rose from 7 in 2008 to 68 by the end of 2014, with about 55 in 2015 
(provisional data) (UNODC, 2016b). Over the period 2005-16 the cumulative number of such 
molecules reported to the EMCDDA was 118, of which 14 were reported for the first time in 2016 
(EMCDDA-Europol, 2017); at the time of writing, 31 October 2017, this total has increased to 128.  
 
 
9.2.3: Number and quantities of cathinones confiscated 
 
The fact that most NPS remain outside international drug control and cannot therefore be seized and 
reported to the UNODC as part of the regular data collection mechanisms, such as the Annual Report 
Questionnaire, means that is difficult to get an accurate picture of their movement and supply. To 
complicate matters further, confiscations of NPS are commonly only notified using a product name or 
at the substance group level, which prevents data from being linked to a specific substance.  
 
Very few seizures of synthetic NPS were reported in 2010, but the UNODC (2017a) reports that in 
recent years 23-54 tons have been seized annually. Whilst global seizure amounts have been 
dominated since 2011 by synthetic cannabinoids, the amount of synthetic cathinones confiscated has 
risen greatly since they were first reported in 2010. In 2010 and 2011 less than 200 kg were seized, in 
2012 and 2013 the quantities doubled to about 400 kg, but seizures trebled between 2013 and 2014, 
reaching a level of 1.3 tons (UNODC, 2016a). In 2014, most synthetic cathinones were seized in 
Eastern Europe (692 kg in the Russian Federation), in Western and Central Europe (312 kg in 
England and Wales) and in East and South-East Asia (226 kg in Hong Kong, China). 
 
The most recent US figures indicate that the number of cathinone ‘exhibits’ submitted to the National 
Forensic Laboratory Information System (NFLIS) increased from 15,523 in 2014 to 19,490 in 2015, 
ethylone accounting for 47% of synthetic cathinone exhibits. (U.S. Department of State Drug 
Enforcement Agency (DEA), 2016). During 2016 most cathinone identifications conducted by the 
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DEA’s Special Testing and Research Laboratory were for dibutylone (22%), followed by ethylone, N-
ethylpentylone and α-PVP; these substances still appear to be most commonly identified in the first 
three quarters of 2017, although there is some variation from quarter to quarter (DEA 2016, 2017a, 
2017b).  
 
The EMCDDA (2017) reports that for the latest annual reporting year (2015) some 80,000 seizures of 
NPS were made through the EU Early Warning System (EWS). Synthetic cathinones accounted for 
the largest class of NPS, some one-third or 25,000+ seizures, an increase of more than 17,000 on 
2014. The quantity of synthetic cathinones seized in 2015 was just over 1.8 tonnes (1.05 tonnes in 
2014). According to the EU EWS, the five most commonly seized cathinones in 2015 were α- 
PVP, 3-MMC, ethylone, 4-CMC and pentedrone. Where information on country of origin is available, 
China accounted for more than 1.2 tonnes of the synthetic cathinones seized in 2015. Of these, 42% 
were 2-MMC (156 kg) and 3-MMC (616 kg). These molecules are chemically related to mephedrone 
(4-MMC), but are not internationally controlled. The EMCDDA (2017) consider it likely that supplies of 
these two molecules are being passed off as mephedrone. 
 
The number of mephedrone seizures made by law enforcement agencies in England and Wales rose 
from 2,002 in 2010/1 (the first full year following control) to a peak of 3,850 in 2012/3 since when the 
number has steadily fallen to 1,031 in 2015/6. Over the same period, the amount of mephedrone 
confiscated has followed a similar trajectory: from 231 kg in 2010/1 to 716 kg in 2012/3, falling to 173 
kg in 2015/6 (personal communication to first author by J. Hargreaves, Home Office Crime and 
Policing Analysis Unit, 24 November 2016). In Scotland the police made around 200 seizures of 
mephedrone each year between 2010/1 and 2012/3 but this has since fallen to only 11 in 2015/6. The 
amount seized rose from less than 6 kg in 2010/1 to 9 – 10 kg in the following two years, but reached 
a peak of about 67 kg in 2013/4 before falling to less than 1 kg in 2015/6 (personal communication to 
first author by H. Mackenzie, Justice Analytical Services, Scottish Government, 3 July 2017). In 
Northern Ireland the number of seizures of mephedrone powder fell steadily from 286 in 2010/1 to 46 
in 2015/6. The amount of mephedrone seized in 2010/1 was 20.9 kg but fell to between 2.3 and 3.9 kg 
in 2011/2 to 2013/4 before falling to 0.4 kg in 2014/5 and 0.1 kg in 2015/6 (personal communication to 
first author by PSNI Statistics Branch, 2 December 2016). 
 
 
9.3: Prevalence 
 
Although mephedrone was first synthesised 90 years ago (Saem de Burnaga Sanchez, 1929), the first 
use of synthetic cathinones for recreational purposes seems to have been in the mid-2000s. The first 
wave or generation of synthetic cathinones to come to the attention of the general public, law 
enforcement and healthcare professionals was methylone in 2005 and mephedrone in 2007. This was 
at a time when the availability and purity of stimulants such as amphetamines, cocaine and ecstasy 
(MDMA) were falling and prices were going up, especially in the UK. Although synthesised in 1969 
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(http://catbull.com/alamut/Bibliothek/Boehringer_MDPV_Patent.htm), MDPV first emerged onto the 
recreational market in 2009; the number of pyrovalerone derivatives has increased greatly in recent 
years (Beck et al., 2017). The second generation of synthetic cathinones, such as naphyrone and 4-
methyl-N-ethcathinone (4-MEC), emerged as replacements for mephedrone, methylone and MDPV 
when these became controlled in 2010. By this time, the so-called third-generation synthetic 
cathinones also began to emerge: 3,4-DMMC (3,4-dimethylmethcathinone), then pentedrone (α-
methylaminovalerophenone) followed by α-PVP (α-pyrrolidinovalerophenone; α-
pyrrolidinopentiophenone) (Valente et al., 2014). 
 
Information on the availability of synthetic cathinones has provided some context against which we 
can examine the extent of their use. However, there are limitations in respect of the sources we can 
use to try and achieve this aim, especially with regard to trend data.  
 
International sources 
 
At the global level, the UNODC has not published any prevalence data for synthetic cathinones as a 
drug class or for individual molecules. However, some national data are available for a few countries. 
 
In the USA little information has been collected on adult cathinone use (Stogner and Miller, 2013). 
However, the Monitoring the Future survey has been monitoring the drug use of college students and 
adults aged 19-55 years since 1975. Rather than looking at synthetic cathinones, they monitor ‘bath 
salts’; however, questions were first introduced only in 2012. This was the first national survey in the 
USA to provide information on bath salts. Whilst the last year use rate was reported in 2012 at 0.8%, 
0.6%, and 1.3% in grades 8, 10, and 12, respectively, by 2016 the levels had fallen to less than 1% in 
all three age groups (Schulenberg et al., 2017).  Whilst 0.8% of high school seniors reported using 
bath salts in the previous year, the level amongst young adults (19-30 years) was typically 0.3%.  
In 2012 the annual prevalence rate for males aged 19-22 years was 3.0% compared to 0.5% amongst 
females of the same age. However, this differential disappeared in 2013, at a time when there was a 
large rise in the perceived risk of harm from using bath salts; such a shift was also seen in older 
groups of young adults, as well as 12th graders (18 years). The fall in the use of bath salts and a rise in 
their perceived risk of causing harm echoes US National Poison Control Centers’ data suggestive of a 
peak occurring in 2012 of their use, with the subsequent decline likely to be due to wide coverage of 
adverse effects in the media. There is currently little variation in last year use of baths salts across the 
different regions of the USA. In 2012 use of bath salts appears to have been higher in small towns and 
farm/country areas, particularly amongst young people, but now rates are very low (less than 1%) 
across all levels of population density. Use appears to be higher amongst non-college respondents 
(0.5%) than college students (< 0.05%) in 2016. A study (Stogner and Miller, 2013) of 2,349 students 
at a South Eastern university in early 2012 found that only 1.07% reported lifetime use of bath salts or 
MDPV; use was higher amongst men (1.7%) than women (0.5%). In terms of ethnicity, the highest 
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rates were for Hispanics (4.7%), followed by Native Americans (4.3%), Whites (0.9%), and Blacks 
(0.7%). Use was more common amongst athletes (4.0%) compared to non-athletes (0.9%). 
 
In Australia, the The Ecstasy and Related Drugs Reporting System (EDRS) has been running since 
2003. EDRS is a national monitoring system intended to identify emerging trends of local and national 
interest in the markets for such drugs. EDRS looks at the price, purity, availability and patterns of use 
of ecstasy, methamphetamine, cocaine, ketamine, GHB, MDA and LSD. However, it also captures 
some information on mephedrone. The 2010 sweep of regular ecstasy users, the first to record a 
synthetic cathinone, found that 21% reported lifetime use of the molecule and 17% had used it in the 
six months prior to interview (Matthews and Bruno, 2010). This was against a background of increased 
difficulty in obtaining ecstasy and lower purity levels. Recent use of synthetic cathinones fell from a 
peak of 18.5% in 2010 to 7.7% in 2015 (Sutherland et al., 2016). Recent use of mephedrone fell from 
16% in 2010 to 13% in 2011 to 5% in 2012 and 6% in 2013, whilst use of MDPV increased from <1% 
to 1% between 2010 and 2011 before increasing to 2.5% in 2012 before falling to back to 15 in 2013; 
methylone use was 5% in 2011 and 2012, but fell to 3% in 2013 (Sindicich and Burns, 2011, 2013). 
Based on multivariable logistic regression analysis of the 2010-5 data, recent cathinone use was 
found to be associated with daily tobacco and poly-drug use. The combined intake of cathinones and 
cocaine was not statistically significant in the study by Sindicich and Burns (2011). Among poly-NPS 
users, in decreasing order to prevalence, recent cathinone use was associated with the intake of 
phenethylamines, tryptamines, synthetic cannabinoid receptor agonists (SCRAs), plants & extracts, 
arylcyclohexamines, piperazines and aminoindanes (Sutherland et al., 2016). 
 
The EMCDDA has not yet collated any prevalence data for NPS; although whatever information that 
exists on specific molecules is presented in their Risk Assessment and EMCDDA-Europol Joint Report 
publication series. Available at: http://www.emcdda.europa.eu/activities/action-on-new-drugs, those 
currently available on synthetic cathinones only relate to mephedrone, MDPV, and α-PVP. It was 
estimated in 2012-3 that last year mephedrone use amongst European adults aged 16-59 years 
reached 0.5% (cited in Karila et al., 2016). Last year use of synthetic cathinones amongst young 
people aged 15-24 in Finland in 2014 was estimated to be about 0.2% (cited in Karila et al., 2017). In 
France MDPV and 4-MEC were in the top 10 NPS sold online in 2010-11 (cited in Karila et al., 2017). 
In 2012, methylone was the 11th most popular hallucinogen in the USA (DEA, 2012). In the Republic 
of Ireland, 3% of clients at a methadone maintenance clinic tested positive for methylone (McNamara 
et al., 2010).  Past year use of injecting methylone was reported by 7% of male and 1% of female Irish 
prisoners in 2011 (Drummond et al., 2014). 
  
In Europe, the Eurobarometer surveys on the attitudes of youth/young peoples’ towards drugs only 
looked at "new substances that imitate the effects of illicit drugs” (http://ec.europa.eu/justice/anti-
drugs/new-drugs/index_en.htm). Also at the European level, there are no international surveys, such 
as European School Survey Project on Alcohol and Other Drugs (http://espad.org/) and the Health 
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Behaviour in School-aged Children (http://www.hbsc.org/) capturing information on use of school-age 
children on either specific synthetic cathinones or these molecules as a drug class.  
 
At the UK level, the Smoking, Drinking, Drug Use survey carried out on behalf of the Department of 
Health (England) has tackled this issue. The most recent sweep found that last year use of 
mephedrone fell from 0.7% in 2012 to 0.5% in 2013 and 2014, and then to 0.4% in 2016 for pupils 
aged 11-15 years; the rate starting off higher for boys (0.8%) compared to that for girls (0.6%) in 2012, 
but both having the same rate (0.5%) in 2014, before falling to 0.4% for boys and 0.1% for girls in 
2016 (NHS Digital, 2017). In 2016, last year prevalence rates increased with age, as might be 
expected, for males from 0.0% for those aged 11 to 1.0% for 15 year-olds; for girls it rose from 0.0% 
aged 11 and 12 years to 0.5% at 15 years. Offers of mephedrone in the last 12 months also increased 
with age, with 1% boys aged 12 first experiencing offers compared to 4% of 15 year-old boys; for girls 
the age at when they were first offered mephedrone was 13 (1%), increasing to 3% by the age of 15 
years. Whilst one-quarter (24%) of pupils aged 11 had ever tried mephedrone, by the age of 15 years 
this proportion had increased to 44% in 2016.  In Scotland, a survey of students in high schools and 
tertiary educational institutions conducted a few years earlier found that lifetime use of mephedrone 
was 20.3%, 4.4% took it daily and 7.6% reported experiencing symptoms of dependence or addiction 
(Dargan et al., 2010). 
 
 
Mixmag/Global Drug Survey 
 
One of the longest running surveys of young people and their recreational drug use patterns is the UK 
Mixmag drug survey associated with the dance music scene, which in recent years has expanded to 
become the Global Drug Survey (GDS). Though international in reach, most respondents are from the 
USA or the UK. The most obvious limitation is that participants are self-selected, thus subject to 
response bias (i.e. those interested in a subject are more likely to respond than those who are not) 
and may not represent all those young people who use drugs recreationally. The GDS uses non-
purposive, non-random, opportunistic sampling methods. 
 
As with other surveys, mephedrone was the first synthetic cathinone to be reported by readers of the 
Mixmag clubbing magazine in its 2010 survey (conducted in 2009), being the fourth most popular 
drug; lifetime use was reported at 41.7% and last month use at 33.6%. It was the sixth most common 
substance used in the month prior to the survey, only bettered by tobacco, alcohol, cannabis, cocaine 
and MDMA. Mephedrone users tended to be younger and male compared to other respondents. Just 
over half (54.6%) of individuals who had also used cocaine reported that mephedrone high was of 
better quality; those using intranasally reported that mephedrone was more addictive and risky than 
cocaine (Winstock et al., 2011a). Lifetime use of mephedrone peaked in 2011 at 61%, as did last year 
use at 51%; these fell to 42.7% and 19.5& respectively in 2012, by which time last month use had 
fallen to 13%. However, last year use by regular UK clubbers was 30% (Winstock, 2012), mephedrone 
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use continued to decline in 2013: lifetime use was 36.1% and last year use was 13.8%. By 2014 last 
year use had fallen in the UK to 7.9%, compared to 1.2% in Hungary (Winstock, 2014). At present, 
there is no information available online regarding mephedrone for the 2015 and 2016 sweeps of the 
GDS; in 2017 lifetime use in the UK was down to 1.9%; no information is given for the UK in respect of 
last year use, but the lowest percentage given for any country was 0.7%, suggesting that the  UK rate 
was lower than that (Winstock et al., 2017). Levels of mephedrone use in the USA appear to be much 
lower than in the UK. For example, in 2012 last year use was reported at only 2%, in 2013 lifetime use 
had risen to 5.3% with last year use at <5% (Winstock, 2012, 2013). 
 
Other characteristics presented in the Mixmag/Global Drug Surveys include: MDPV first emerged in 
the 2011 sweep with lifetime use reported at 4.4% and last year use at 3.0%; a year later use in the 
previous 12 months had fallen to 0.5% (Winstock, 2012). In 2012, 70% reported snorting mephedrone, 
and 20% swallowed the substance. The following year the proportion snorting had increased to 86% 
and that swallowing had fallen to 12% (Winstock, 2012, 2013). Nearly half (49%) of respondents in 
2012 thought the purity of mephedrone had fallen compared to the previous year; its value for money 
being rated 5.8 out of 10 in 2013 (Winstock, 2012, 2013). In 2013, the typical price for 1 g of 
mephedrone was £20, although 47% of UK respondents typically paid less; prior to mephedrone being 
controlled in April 2010 the price for 1 g was about £10. Over half of respondents (56%) typically used 
0.25 to 1 g in a normal session; 10% reported normally using >2g, whilst one-third (33%) had 
consumed > 2g in a single session and 11% > 7g in a single session (Winstock, 2013). 
 
 
Additional United Kingdom data 
 
According to the 2016/7 sweep of the Crime Survey for England and Wales (CSEW), lifetime use of 
mephedrone by 16-59 year olds rose from 1.9% in 2012/3 to 2.3%  the following year but has now 
fallen to 1.8%: rates for 16-24 year olds over the same period rose from 4.5% to 6.3% before declining 
to 3.3%. The rates for last year use have fallen for the wider age group from 1.3% in 2010/1 to 0.1% in 
2016/7; amongst young people the fall was from 4.1% to 0.3% (Broadfield, 2017). These rates 
represent a fall from an estimated peak of 211,000 reporting use in the year prior to the survey in 
2013/4 to only 48,000 in 2016/7. Combining the results from the 2013/4 and 2014/5 sweeps of the 
CSEW shows that mephedrone was the most likely drug to be used simultaneously with other drugs 
(68%), compared to ecstasy (57%) and amphetamines (50%) (Lader, 2015). 
 
In Ireland and Northern Ireland, NPS use among persons aged 15-64 years dropped significantly 
between 2010/11 and 2014/15 according to the fourth drug prevalence survey of households in Ireland 
and Northern Ireland (National Advisory Committee on Drugs and Alcohol & Department of Health 
Northern Ireland, 2016). In Northern Ireland specifically, lifetime use of mephedrone rose from 2.0% to 
2.5% between 2010/1 and 2014/5, whilst last year use fell from 1.1% to 0.5%, but last month use rose 
from 0.1% to 0.3% in the same period. Mephedrone usage rates were higher for males than for 
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females in both periods: lifetime 3.1% and 3.6% for males vs. 0.9% and 1.4%; last year 1.9% and 
0.9% vs. 0.3% in both years; last month 0.1% and 0.5% vs. 0.0% and 0.1%. There were higher rates 
for those aged 15-34 years compared to those aged 35-64 years: lifetime 4.3% and 5.1% vs. 0.4% 
and 0.7%; last year 2.2% and 1.2% vs. 0.3% and 0.1%; last month 0.1% and 0.5% vs. 0.0% and 
0.1%. The declines noted both for NPS and also for mephedrone in Northern Ireland occurred during a 
period during which national controls on NPS were introduced by both governments and government 
agencies were raising the awareness of drug users to the health risks associated with NPS. 
 
Both the general household surveys and the Mixmag/Global Drug Surveys have demonstrated a fall in 
the use of mephedrone in recent years, although the timing is different according to the source, e.g. 
2011 in the Mixmag/Global Drug Surveys but 2013/4 according to the CSEW, and 2014/5 in Northern 
Ireland. These patterns may represent a demonstration of how the diffusion of certain drugs may first 
appear and peak in specific sub-populations, such as the gay community, before spreading to the 
dance music scene and then spreading to the wider community. 
 
It is noticeable, that levels of mephedrone use, in particular, were highest within the gay community, 
even after the UK government introduced controls. Mephedrone emerged from near obscurity to 
become the most popular illegal drug in a survey of 308 clients of two South London gay dance clubs 
in July 2010 (Measham et al., 2011). Just over half (52%) of respondents had used mephedrone in the 
last year, 41% had taken it in the past month and 27% had either taken and/or were planning to take it 
on the fieldwork nights. The second-generation cathinone “NRG-1” (naphyrone) had been taken by 
11% of the sample in the past month and 3% had taken and/or planned to take it on the fieldwork 
night. Only cocaine was used more frequently than mephedrone; last year use was 59% and last 
month use was 44%. The majority (75-80% depending on the form) of  last month ecstasy users had 
also used mephedrone during this period, as had two-thirds of cocaine users. Rather than displacing 
or replacing such stimulants, mephedrone  became part of the club drug reportoire, reflecting the trend 
over recent years towards poly-substance use (Moore et al., 2013). These findings are replicated by 
another study looking at drug use in similar venues a year later: mephedrone had the highest 
prevalence of last month use (53.2%) and use on the night of the survey (41.0%); this compares with 
both cocaine (44.6% and 16.7% respectively) and MDMA/ecstasy (26.9% and 5.8% respectively). 
Other ‘legal highs’ were used ‘on the night’ to a more limited extent: methoxetamine (1.6%) and 1-
benzylpiperazine (0.6%), Spice/K2 (0.6%) and pipradrols (0.6%) (Wood et al., 2012). 
 
In France, research into the chemsex phenomenon found that across 13 Addictovigilance centres 
between 2008 and 2017, synthetic cathinones occupied 7 out of the 12 psychoactive substances 
used, in descending order: 4-MEC (61); 3-MMC (48); mephedrone (47); MDPV (17); methylone (4); 4-
P (3); and α-PVP (2). This compares to cocaine (52), GHB/GBL (45), methylamphetamine (20), 
ketamine (11), and MDMA (6); most of these are stimulants. The relative proportions of cathinones in 
the Addictovigilance database for 2008-2017 were : 4-MEC (34%); 3-MMC (26%); mephedrone (26%); 
MDPV (9%); methylone (2%); 4-P (2%); α-PVP (1%). Mentions recorded by the national French 
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Helpline during 2014-7 were: 4-MMC/mephedrone (49%); 3-MMC (22%); 4-MEC (16%); MDPV (9%); 
methylone (2%); 2-MMC (2%); and α-PVP (1%) (Djezzar et al., 2017). 
 
More generally, we can summarise that recent studies indicate that mephedrone, and most likely other 
synthetic cathinones, have been added to the established repertoires of psychostimulants instead of 
replacing or displacing ecstasy and cocaine (Schifano et al., 2017). 
 
 
9.4: Investigating motivations for using psychoactive substances 
 
Understanding motivations for drug use at an individual level helps to provide information on what 
factors might drive change(s) in the drug market(s) including the impact of policy changes (Reuter and 
Pardo, 2017). Such insight can facilitate effective harm-reduction initiatives, and help to anticipate 
what psychoactive substances may (re-)emerge in the future (Sutherland et al., 2017). 
 
There are a number of ways in which we can gain an insight into the opinions, beliefs, desires and 
motivations of individuals. At a population level, we have exploited the use of various types of surveys, 
with a range of theoretical and practical challenges, to see what we can understand about the nature 
and extent of synthetic cathinone use. However, these patterns are an aggregation and cumulation of 
multiple and complex decisions by individual members of communities and societies. Reports from 
medical settings and poison information centres do not provide information about reasons for 
consumers starting use of these molecules (Ashrafioun et al., 2016). 
 
For an insight into what factors may infuence and shape these decisions, as well as the nexi within 
which they are made, and thus try and understand such processes, it is necessary to consider 
individual experiences and lives. This could be done through a variety of ethnographic approaches: 
from individual interviews and focus groups, where access to the target population is straightforward, 
to using more indirect approaches as netnography (Kozinets, 1998). Here, methods such as 
conducting thematic analyses of discussions in online drug user fora, postings on social media 
resources such as YouTube, Facebook, Twitter, Instagram, etc., as well as experiences collated by 
databases such as Erowid (https://www.erowid.org/) can be employed (Davey et al., 2012; Deluca et 
al., 2012). For some at-risk groups, other types of survey have to be used e.g. online surveys 
advertised on user fora. These can also be used to find out about what people are using, how and 
when, why and where, effects (desired and unwanted) using a netnographic approach (Orsolini  et al., 
2015a). User fora on the open Web and the DeepWeb can not only be used to investigate such as 
aspects but also can be used to find out about prices, purity, availability, suppliers, etc. (Corkery et al., 
2017). 
 
Recently, more advanced techniques, such as social network analyis and analytic tools developed for 
‘big data’, have been introduced from the related field of digital ethnography. For example, using 
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20,000+ drug experiences reported on Erowid, Krieg et al. (2017) argue for the integration of 
computational and digital data analyses with traditional ethnographic methods. The authors state that 
their study provided useful insights into the interconnections and relationships across several domains, 
e.g. drug phenomenology, consumption and harm reduction. This deeper understanding at the 
collective individual level helps researchers to make sense of developments at the wider social level 
(Kozinets, 2015; Krieg et al., 2017). Triangulation of information is important as this makes research 
findings more robust, reliable and generalisable. 
 
 
Motivations for use of any drug 
 
One can draw a distinction between motivations (which may include more subjective influences) and 
reasons (which may be more objective, logical, rational and determined, in part, by external 
influences) for the use of psychoactive substances.  
 
The reasons for an individual using a psychoactive substance can be straightforward and singular or 
complex and multidimensional. To take alcohol as an example: on the surface, a consumer may 
consume an alcoholic drink just to enjoy its effects. However, if one starts to consider the context of its 
use, a wider range of possible influences may be seen as influencing its consumption, e.g. the effects 
may be more apparent in a specific setting, with certain other individuals, at a particular time, etc. In 
turn, these may be influenced by perceived needs to ‘fit in’ with or ‘belong’ to a particular social group 
(i.e. to have some sort of ‘identity’), to socialise, to not feel isolated, etc. 
 
Dimensions along which motivations (including desires, wants, and needs) for drug use can be 
described could include: 
 
• Religious/spiritual – as part of a religious ritual (to celebrate ‘sacraments’ as in ‘taking 
’communion’ using wine or marijuana); to be ‘cleansed’ or ‘purified’ (e.g. ayahuasca); to 
accompany reading a Holy Book; to enhance ‘enlightenment’, to commune more directly with 
deities or other spiritual forces; 
 
• Exploratory/experimentation/curiosity – this can range from scientists (such as the late 
research chemist Alexander Shulgin) designing new molecules, self-experimenting with them 
and recording their effects, to ‘e-Psychonauts’ who intentionally experience drug-induced 
altered states of consciousness so as to try investigating their minds, and possibly address 
spiritual questions, through such direct experiences, through to ‘creatives’ such as artists, 
designers, musicians, writers, philosophers, thinkers and even academics using psychoactive 
substances to be more original, innovative and ‘thinking outside the box’ to achieve new 
insights or understandings of phenomena in the world(s) around them. 
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• Social/cultural – being part of a social (including religious) group will lead to expectations on 
the part of others that individuals will conform to particular norms, practices and customs (e.g. 
peer pressure), thereby confirming their allegiance or belonging to that group; symbolic 
evidence of this relationship may have to be demonstrated through the consumption of a 
psychoactive substance, such as at an initiation ceremony, a ‘rite of passage’, etc. Regular 
consumption, at regular intervals and settings, may help to reinforce this sense of belonging, 
e.g. “going out with the boys/girls” to the local bar or pub on a Friday or Saturday night. 
Loyalty to a group, a nation or its leader may be customary at formal occasions, e.g. ‘toasting 
the bride and groom’ or ‘toasting the Queen’.  
 
• Recreational – drug use is often associated with particular types of music scene, with specific 
drug classes being linked to individual genres of music, e.g. ‘dance club’ drugs; these scenes 
and their associated drug repertoires can be fluid and evolve; 
 
• Employment/occupational – it may be necessary to taste psychoactive substances as part of 
one’s occupation e.g. wine-taster, brewer, whisky-blender, law-enforcement agent, etc.; to 
consume it as a religious leader  or practitioner (priest, shaman, etc.) during a religious 
service/rite, e.g. a ‘sacrament’ such as ‘communion’ or performing an exorcism; to facilitate 
business transactions; 
 
• Therapeutic – this could be preventative or to cure (e.g. ibogaine to cure addiction to drugs), 
to deal with symptoms of a disease or mental health problem (whether prescribed by a health 
professional or self-medicated), to enhance the effects of another psychoactive substance, to 
ameliorate the side-effects of another psychoactive substance e.g. during ‘come-down’ or to 
facilitate withdrawal; 
 
• Addiction/Dependence – physiological/chemical dependence as well as psychological 
dependence on, ‘craving’ for, etc. a substance may develop; the abrupt cessation of use may 
be potentially life-threatening in some extreme cases. 
 
• Functional – searching for energy (Cadet-Taïrou, 2016); to be alert/stay awake; to stave off 
hunger, suppress appetite, and weight-loss; passing time/ avoiding boredom, etc. (Van Hout 
and Hearne, 2015). 
 
 
These dimensions may well overlap, the boundaries can be blurred and intersect with one another, 
having different significances as the drug using career/history of an individual evolves. The themes 
above will be echoed in the following sections. 
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Motivations for using NPS 
 
The reasons for using NPS and in what contexts are likely to reflect those for illegal drugs: socio-
cultural, religious, and recreational use; therapetic/self-medication; functional goals;  and 
exploratory/experimentation/curiosity. Typical reasons for using ‘legal highs’ include curiosity, pleasure 
and to get ‘a better high than illegal drugs’ (Norman et al., 2014). Initial experimentation and continued 
use may also be driven by such factors as boredom and peer socialisation (Van Hout and Hearne, 
2015). 
 
Factors specifically encouraging NPS use include: they are comparatively easier to source; their lower 
price; and (assumed) better quality and safety compared with traditional drugs. For individuals and 
groups subject to drug screening, such as prisoners, armed forces, law enforcement agencies, 
hospital in-patients, individuals undergoing drug treatment or detoxification, drivers of vehicles, trains, 
aircraft, etc. and the assumed, and actual, non-detectability in tests of NPS can be an important factor.  
 
However, the creation and continual evolution of the Internet and social media appear to effect NPS 
use, especially ‘legal highs’, in additional ways and for additional reasons, including: no stigma being 
attached to their use; they are easily available; they can be purchased anonymously online; and there 
is no need to have a prescription for medications.  
 
The development of the so-called ‘Drugs 2.0’ Internet has helped to facilitate a new drug ‘scenario’, 
where a new generation of users possessing quasi-expert pharmacological and chemical knowledge 
and ideas regarding NPS and/or combinations of NPS and known molecules to share information via 
virtual platforms (Power, 2013; Schifano et al., 2006). Such e-Psychonats also sell and buy NPS and 
other novel substances through this new cybermarket (Orsolini et al., 2015b; Power, 2013, Schifano et 
al., 2006). These self-experimenting psychonauts historically typically investigated the "inner 
universe"/"Psychocosmos" (Jünger, 1970), often through psychotropic (“turning towards the psyche”) 
drugs (Labate and Jungaberle, 2011). These days, they could be referred to as pharmacological 
’trippers’ (Corkery et al., in press), since, as we saw earlier, they are individuals who deliberately 
experience states of altered consciousness, that are drug-induced to try and explore their minds, and 
find answers to spiritual questions via direct experiences (Power, 2013; Labate and Jungaberle, 2011; 
Carroll, 1987).  
 
Drug use by psychonauts can be regarded as somewhat similar to ritual plant consumption by ancient 
and current shamans from an anthropological point of view, as they appear to favour mostly NPS with 
hallucinogenic/entheogenic properties (Orsolini et al., 2016, 2017). However, some consumers of NPS 
see a clear distinction between the neo-shamanic practices of psychonauts’ mental exploration and 
genuine shaman practice that is healing focused (Power, 2013). Like shamans, e-Psychonauts may 
be conceived as a ‘sub-cultural virtual group’, and similarly their  chief beliefs and goals often have 
more to do with the achievement of altered states of consciousness rather than with recreational 
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purposes (Psychonauts.com, 2017; Reddit.com, 2017). It could be argued (Corkery et al., in press) 
that the cultural reputation and attraction of NPS mainly derives from their use among e-Psychonauts  
(Deluca et al., 2012), whose extensive information and experience sharing on the Internet facilitates 
the difusion of the ‘psychonaut cultural phenotype’ (Psychonauts.com, 2017). 
 
Earlier, we observed that the context or setting of drug use can influence what is taken. Taking the 
example of music, Cadet-Taïrou (2016) notes the association of phenethylamines with the ‘electro’ 
music scene in France. A range of external factors may influence NPS use in recreational night-life 
settings: the lower the age and educational level of users the more likely they were to consume NPS in 
a private setting (home of the user or a friend) rather than in a public setting such as a party or other 
event; occupational status and whether the consumer is the main salary earner in a household can 
also influence use of NPS. 
 
As with traditional recreational drugs, temporal patterns can be observed in the consumption of NPS 
(Corkery et al., 2015). For example, α-PVP, BZP, mephedrone and methylone were mostly used at 
weekends, similarly to the pattern reported for cocaine and MDMA, whilst opioids and cannabis were 
used at a consistent level through the course of the week, in a study of waste-water samples analysed 
in Adelaide, Australia, between 2011 and 2015 (Tscharke et al., 2016). 
 
It was noted earlier that NPS use is higher in some groups compared to the general population, 
including: young people; people in contact with mental health services; the homeless; people who 
inject drugs (PWID); and men who have sex with men (MSM) (UNODC, 2017a). A recent Scottish 
study found that amongst such groups, synthetic cannabinoids were used by 41% of subjects and 
mephedrone by 19% (MacLeod et al., 2016). Marginalised groups, including the young, socially 
disadvantaged and homeless with little disposable income, are more likely to be attracted to NPS as 
they are cheaper but have similar effects (MacLeod et al., 2016; NDEWS, 2016). 
 
Economic factors (drivers, pushers) such as demand and supply, have been associated with the 
emergence of NPS in relation to the market for traditional recreational drugs, and the subsequent 
establishment and evolution of the NPS market (Tscharke et al., 2016; Van Hout and Hearne, 2015). 
Eight years ago the main drivers for NPS use were the poor quality of traditional drugs, especially 
cocaine, amphetamines and ecstasy/MDMA, and their lack of availability and high price (Corkery et 
al., in press; Guirguis et al., 2017); ease of access on line, ‘value for money’, rather than their apparent 
safety (assumed because of their ‘quasi-legal’ status) are now the impelling forces, as the quality of 
such traditional drugs has now recovered to (Winstock et al., 2016; MacLeod et al., 2016) or exceeded 
their former levels.  
 
 
Reasons for using natural cathinones (khat) 
 
@ 13 November 2017 
18 
 
Cathinone, one of the principal psychoactive constituents of khat (Catha edulis), a Central Nervous 
System stimulant acting on the dopaminergic and other pathways, was assessed in 1985 as being half 
as potent as amphetamine whilst cathine was assessed as being 7-10 less potent than amphetamine. 
In many countries the plant is still legal and available, although this  situation is changing rapidly. 
These active ingredients, so-called ‘natural amphetamines’, can be extracted through chewing, but 
maximal plasma levels take a long time to achieve in order to give a ‘buzz’ or a ‘high’; therefore, khat’s 
reinforcing properties are far less than other stimulants, e.g. amphetamine and cocaine.  
 
Traditional medicine has been a milieu within which khat has played a long-term role: as a treatment 
for depression, gastric ulcers, hunger, obesity and tiredness; to relieve vomiting, stomach ache, 
influenza ; to counter the effects of  binge-drinking and hangovers; to treat asthma, coughs and other 
respiratory conditions; and as an aphrodisiac (Corkery, 2016). In recent decades, khat has been seen 
as a ‘refuge’, as a means to mediate stress and trauma occasioned by civil war and cultural 
dislocation, helping to ‘kill time’, and forget the troubles of the past. It may help young people deal with 
the frustrations of a lack of employment and boredom. 
 
Within the male community, khat chewing helps individuals to socialise, facilitate business deals, and 
the venues where it is consumed provides a context for net-working, sharing information and social-
bonding; for females it is mostly for social purposes. As khat-chewing is primarily culturally-bound, it 
help provides a sense of ‘belonging’ and social cohesion. Leaves are chewed whilst small groups 
gather to recite verses from the Koran. 
 
Other functional aspects continue to be important: khat acts as an aid to concentration and prevents 
sleep whilst studying, thereby improving the chances of academic performance (not proven); helping 
drivers, night guards, etc. to remain alert and vigilant; provides energy, improved performance and 
thus increased productivity. These are the main benefits put forward for khat’s use, along with it acting 
as an aid to rest and relaxation. 
 
 
Why individuals use synthetic cathinones 
 
There is considerable overlap between the reasons for using khat and for using synthetic cathinones. 
A range of reasons are reported, including: hallucinogenic experiences, euphoria, mood 
enhancement, openness in communication, empathy, mental clarity, increased alertness, insomnia, 
stimulation, intensification of sensory experiences, increased energy, reduced appetite, increased 
sociability, increased libido and sexual performance (Rosenbaum et al., 2012; Schifano et al., 2016), 
increased confidence (Brookman et al., 2017). ‘Problem reduction’ is also reported, e.g. mephedrone 
being taken to alleviate psychological problems and to help deal with emotional issues (Brookman et 
al., 2017).  
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Motivations for use of synthetic cathinones have varied over time, in different countries and amongst 
different user groups. These differences may be due, in part, to the varying patterns in the pace at 
which the knowledge of and use of synthetic cathinones have spread. For example, mephedrone use 
first emerged in ‘sentinel’ groups such as the ‘gay’ community in London before going mainstream in 
the UK and other European countries, before the bath salts craze hit the USA. By this time, MDPV 
was entering the scene and thus the North American experience was not identical to the European 
one. The highest number of calls to national poison information centres in the USA happened more 
than a year after the peak in the UK (Spyker et al., 2012). 
 
Increased availability, ease of purchase via the Internet, perceived legality, assumed high purity, 
perceived better high, fewer side-effects, safer to use and short duration of action have all been cited 
as reasons for using synthetic cathinones by a sub-sample of ecstasy users in Australia in 2014 
(Sutherland et al., 2017). In previous years, surveys of and interviews with users suggested that the 
increased popularity and convenience of purchasing mephedrone was associated with the 
unavailability, high price and impurity of several stimulants, chiefly amphetamine, cocaine and MDMA 
(ACMD, 2010; Carhart-Harris et al., 2011; Measham et al., 2010). 
 
Data collected between April and September 2014 in Hungary from 198 opioid substitution therapy 
clients showed that these users substituted heroin for NPS, mainly cathinones, because of practical 
issues in obtaining and using the drugs rather than a preference of their psychopharmacological 
effects. In decreasing order of significance, these reasons included curiosity, replacing other drugs, 
increased availability, because their friends used it, more intense subjective effects, low price, legal 
status, poor detectability, exotic brand name, perceived safety, shorter effect duration and attractive 
packaging. Patients who shifted and substituted their opioid dependence to cathinones favoured 
mephedrone, methylone, 4-MEC and MDPV (Kapitány‐Fövény et al., 2017; Brettville-Jensen et al., 
2013). Brettville-Jensen et al. (2013) added that perceived lack of long- or short-term harm, good 
ratings from peers or on the Internet, good quality substitutes of low purity cocaine and ecstasy at the 
time, lack of detection, with an effect that mimics that of ecstasy and other club drugs, are other 
motivations for use of cathinones. Other practical reasons put forward by users include the range of 
methods by which they can be used (Brookman et al., 2017).  
 
Medical practitioners, and users, report that the high from mephedrone lasts longer than that from 
heroin, requires fewer ‘hits’, can lessen the withdrawal effects of heroin, and may assist in harm-
reduction through users migrating from heroin and crack cocaine (with their associated addiction and 
withdrawal problems) to mephedrone (Brookman et al., 2017).  
 
In the context of chemsex, Djezzar et al. (2017) report the reasons for cathinone use, in descending 
order of importance, as: increasing sexual pleasure (> 80%); alter consciousness (c. 70%); hard sex 
(c. 70%); disinhibition (c. 60%); atypical sexual behaviour (c. 45%); prolonging erection (< 10%). 
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Consumption with other substances 
 
Combining use of synthetic cathinnes with the other classes of psychoactive drugs, particularly 
stimulants, is very common and to be expected in today’s poly-pharmacy recreational drug scene(s), 
as are counter-acting classes such as downers (sedatives, opiates/opioids, benzodiazepines, 
GHB/GBL and dissociatives). These drug classes can include prescription drugs, anaesthetic agents 
and alcohol (Valente et al., 2014).  
 
Consumption of synthetic cathinones with other psychoactive substances may occur since, as with 
other drug types, they may counter-act the side-effects (e.g. taking alcohol after consuming 
mephedrone to reverse its side-effects) or prolong the desired-for effects of a molecule, or enhance it 
in some other way, e.g. make it more potent. Different combinations may be used in different settings 
and for different purposes For example, mephedrone may be consumed during partying alongside 
cocaine, MDMA, GBL (γ-butyrolactone) and ketamine (Kirby and Thornber-Dunwell, 2013), whereas in 
‘chem-sex’ sessions MDMA, GBL and methamphetamine may be co-ingested with mephedrone 
(Bourne et al., 2015). Such combinations induce intensified sexual experiences and increased 
disinhibition (e.g. leading to risky behaviours, including not using protection during sex, and having 
multiple partners) (Batisse et al., 2016; Dargan et al., 2011; Karila et al., 2015). 
 
Experiences shared on Bluelight and Drugs-Forum between 2010 and 2015 included:  mephedrone 
being used with Viagra (Cialis) to boost libido and improve sexual perforamnce (e.g. prolonging 
erection); 4-MEC with ‘weed’ and GBL during ‘chemsex’ sessions (Drugs-Forum, 2010a, 2010b, 
2015); MDPV with cocaine; amphetamines and methamphetamine for their entactogenic effects; 
MDPV with beta-blockers to counteract tachycardia; MDPV with GHB/GBL, and 5-MeO-MiPT (5-
methoxy-N-methyl-N-isopropyltryptamine) to improve libido; MDPV with zopiclone to enhance visual 
hallucinations; caffeine for its stimulant effect; famotidine, omeprazole and domperidone to counteract 
stomach pain; and benzodiazepines for their anxiolytic effects (Coppola & Mondola, 2012; Katz et al., 
2014). 
 
Amphetamines, cocaine and ecstasy tablets may be singly or in combination with cathinones to 
maintain arousal and a state of alertness, since MDMA/serotonergic stimulant and entactogenic 
effects wear off after a few hours (Schifano, 2004). Theoretically, potential interactions occur between 
cathinones and prescribed medications. For example, the monoamine oxidase inhibitor moclobemide 
can be taken to enhance the effects of ecstasy-like stimulants (Vuori et al. 2003). These or selective 
serotonin reuptake inhibitors (SSRIs) could interact to induce Serotonin syndrome (Green et al., 1995), 
which can be fatal (Schifano, 2004). Such an outcome can occur when serotonergic release is 
intensified by parallel use of dopaminergic stimulants, such as cocaine and amphetamines (Huether et 
al., 1997; Schifano, 2004). Ketamine and/or LSD together with stimulants/cathinones can increase the 
likelihood of idiosyncratic/intoxicated 'behaviour', such as dangerous driving, with a consequent higher 
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risk of a lethal outcome.  Concurrent use of sedatives could ameliorate excess sympathomimetic 
overactivity observed with stimulant use, including cathinones (Schifano, 2004). 
 
Reasons for using certain psychoactive substances are arguably wider than purely intentional 
motivations, as in the sense of a desire, or more strongly a craving for consuming them. Use of 
synthetic cathinones may be symptomatic of wider influences at work. For example, a representative 
sample of 30,377 US adolescents from the 8th, 10th and 12th grade participating in the Monitoring the 
Future study from 2012-2014 showed that motivation for use of both SCRAs and synthetic cathinones 
was correlated with truancy, cigarette smoking, the use of alcohol and marijuana (Patrick et al., 2017). 
 
 
Comparison of synthetic cathinones with other stimulants 
 
Whilst some cathinones have behavioural effects, respectively, similar to amphetamine or 
methylamphetamine and cocaine, others produce effects that are closer to those of MDMA. Typically, 
four categories of synthetic cathinones are described (Guirguis et al., 2017):  
 
• Cocaine-MDMA-mixed - e.g. mephedrone, 4-MEC, methylone, etylone, butylone and 
naphyrone. Such molecules are substrates for the dopamine transporter (DAT), serotonin 
transporter (SERT), and norepinephrine transporter (NET). When ingested orally these  
molecules are associated with an entactogenic, MDMA-like, effect, but when administered 
intranasally they have a psychostimulant cocaine-like effect (Liechti, 2015); 
 
• Methamphetamine-like - e.g. cathinone, methcathinone, flephedrone, ethcathinone and 3-
fluoromethcathinone. Such molecules are monoamine transporter substrates with DAT 
selective profiles, exhibit high inhibitory potencies at DAT and show lower inhibitory potencies 
at SERT (Simmler et al., 2013, 2014). Similar to methylamphetamine, they induce DA and NE 
release (Liechti, 2015); 
 
• MDMA-like - e.g. methedrone and 4-trifluoromethylmethcathinone. Such molecules show a 
greater inhibitory potency at SERT compared to their inhibition of DAT, whilst inducing release 
of both NE and 5-HT like amphetamine analogues such as MDMA, 
paramethoxymethamphetamine (PMMA), paramethoxyamphetamine (PMA), 4-
ethylthioamphetamine (4-MTA) (Simmler et al., 2014). 
 
• Pyrovalerone - e.g. pyrovalerone, MDPV and α-PVP. Such molecules are non-substrate 
transporter inhibitors, exhibiting inhibitory potencies at DAT and NET equal or greater than 
cocaine (Baumann et al., 2013) or methylamphetamine (Aarde et al., 2013). Both MDPV and 
α-PVP are regarded as cocaine-like molecules (Smith et al., 2017). However, recent research 
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suggests that the pyrovalerone analogue α-PVT possesses rewarding and reinforcing effects 
akin to both cocaine and methylamphetamine (Cheong et al., 2017). 
 
Some users reported that a cathinone-induced stimulant effect is comparable to methylphenidate at 
low doses or to a combined effect of both amphetamine and cocaine at high doses (Coppola and  
Mondola, 2012). Others consider cathinones to be pharmacologically similar to and as potent as  
amphetamine, cocaine, and MDMA (EMCDDA, 2012a). 
 
The ‘honeymoon’ period for mephedrone lasted for a few years. It slowly became apparent that 
compared to cocaine and MDMA, mephedrone had some less favourable effects. Winstock (2012) 
reports that users ceased their ‘love affair’ with mephedrone, in part, due to its higher scores for 
extreme agitation, headaches, tremors, nausea and feeling depressed after use, and to a lesser extent 
paranoia and chest pain.  In terms of positive effects of using drugs, mephedrone came second out of 
ten drugs for increased pleasure from social interactions, but had more negative effects, i.e. first  for 
not being able to function normally in the days after use, negative effects on mental health; second for 
negative effects on ability to work/study/progress, negative effects on physical health; third for 
unpleasant physical and psychological effects when intoxicated (Winstock, 2013). 
 
 
Use of specific types of synthetic cathinones 
 
Typically, the literature classifies cathinones according to their pharmacological action and in 
comparison to more traditional stimulant drugs. However, there is no consensus on how to do this, or 
the categories to be used. Some approaches look at effects in terms of different substrates or non-
substrate transporter inhibitors (Simmer et al., 2013). Others draw comparisons with certain ‘classical’ 
classes of traditional drugs of abuse, i.e. MDMA, amphetamine/methylamphetamine, cocaine 
(Concheiro et al., 2013), or even combinations such as MDMA/cocaine, together with chemical 
structure categories (Valente et al., 2014; Concheiro et al., 2013; Assi et al., 2017). Some of these 
approaches also single out pyrrolidines as a separate group. These approaches lead to overlapping of 
categories and blurred distinctions. 
 
Attempting to establish a connection between different types of cathinones based on their DAT/SERT 
inhibition ratio, structural characteristics or other parameters and their similarity to traditional 
stimulants is difficult in the context of non-psychonaut consumers. An ideal solution in terms of 
categorising synthetic cathinones would be to employ a single criterion in terms of their similarity to the 
effects of ‘classical’ drugs of abuse. Therefore, a pragmatic approach has been adopted for a study 
being conducted by the lead author and colleagues into motivations for using specific types of 
synthetic cathinones, i.e. similarity to the effects of these classical drugs or combinations thereof, and 
the pyrrolidine group: amphetamine/methylamphetamine-like; cocaine-like; MDMA-like; MDMA- + 
cocaine-like; and pyrrolidines/pyrovalerone-type.   
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However, there are problems with ascribing particular effects to specific cathinone molecules or 
particular classes or families of cathinones.and asking users about them. The wording of questions 
has to be very clear as to which of these is actually being asked about. It is unlikely that a non-
pyschonaut user will appreciate the distinction. It may even be the case that only very few 
psychonauts will feel it necessary to distinguish in this way what they consume.  
 
The number of papers which have come closest to achieving this is very small, i.e.: Winstock et al. 
(2011a); Cahart-Harris et al. (2013);  Johnson and Johnson (2014); and Ashrafioun et al. (2016). The 
first paper demonstrated that a web-based survey recruiting from an existing survey (Mixmag) could 
be employed to study users’ experiences, but only contained a limited number of questions exploring 
motivations for use of particular types of synthetic cathinones. The second study also used a web-
based survey, recruiting through advertisements on user fora, to ask about specific subject effects but 
did not investigate reasons for use. The third study followed a similar recruitment strategy to the 
second one and did get some information on reasons for using ‘bath salts’ as a generic class of drug: 
curiosity; mind/brain exploration; liking the effect; to remain alert/awake; to avoid failing drug tests; to 
enhance sexual experiences.  
 
The fourth study listed above, set out to overcome the limitations of the previous three, using online 
recruitment through advertisements on specific websites; put a recruitment video in YouTube and 
purchased targeted advertsements on Facebook (Ashrafioun et al., 2016). The commonest reasons, in 
decreasing order for first trying synthetic cathinones were: curiosity, believing incorrectly that they 
were taking another substance; social pressure; having been offered ‘bath salts’. The main reasons 
given for consuming ‘bath  salts’ were: fun/enjoyment/euphoria/rush; curiosity/new experience; 
substitution for another drug; being at a party/event. The authors note that the effects and motivations 
echo those who use other illegal stimulants, and are similar to those of the previous three studies.  
 
The co-consumption of several synthetic cathinones may occur. If a drug user consumes a branded 
product they may unintentionally take a number of different synthetic cathinones at the same time, as 
suppliers may seek to use up old stocks of molecules which have subsequently become regulated or 
controlled, to test the market with ‘new’ molecules, or to produce several different effects. Many of the 
structural pyrovalerone analogues that replaced MDPV in the cathinones market possess similar 
mechanisms of action and pharmacological effects. As these molecules were offered for sale with the 
same brand names, this fact was not evident to buyers or to consumers (Beck et al., 2016). During the 
period January 2011 to March 2016, the STRIDA project in Sweden recorded 11 pyrovalerone drugs 
in addition to MDPV and α-PVP across 114 intoxicated patients with 149 total pyrovalerne-type 
findings; only 8 patients had used a single cathinone, one patient had used 5 pyrovalerone molecules 
in combination. Co-administration of pyrovalerones and/or use in combination with amphetamines 
suggests that rather than using a specific pyrovalerone, patients were principally interested  in 
obtaining a central stimulatory effect (Beck et al., 2017). Discussions on online user fora also suggest 
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that as well as suggesting particular combinations of cathinones, some suggest combining 4-MEC with 
the amphetamine-type 4-FA (Van Hout, 2014). 
 
In addition to this, adulterants and cutting agents may be added to counter-act side-effects, or since 
they have a similar chemical structure to index molecules they may add to the complexity of the 
mixture, and have a stronger /masking detection signal hindering identification (Guirguis et al., 2017). 
On the other hand, some branded products may contain undisclosed synthetic cathinones; this could 
be very dangerous for consumers. 
 
Reasons for the deliberate consumption of several cathinones may include, one could conjecture, a 
desire to self-harm or to attempt suicide (perhaps as ‘a cry for help’ or as a serious but unsuccessful 
attempt to kill oneself). Such a reason may be due to the panoia or depression induced by synthetic 
cathinones (Corkery et al., 2012). Another reason for co-adminstering cathinones, may be a belief that 
taking two or more synthetic cathinones simultaneously can cause a synergy between them, leading to 
an enhanced experience (Iversen et al., 2014). Rat studies suggest that the co-adminstration of 
MDPV, mephedrone, and methylone  may intensify their associated neurochemical effects via a 
sustained increase in DA and 5-hydroxytryptamine (5-HT) in various brain regions through an additive 
effect (Allen-Campbell et al., 2016). Binary mixtures of common ‘bath salts' constituents (i.e., MDPV, 
methylone, and caffeine) are generally additive in nature; however, both supra-additive 
(MDPV+caffeine and methylone+caffeine) and sub-additive interactions (MDPV+methylone) can be 
observed (Collins et al., 2017). 
 
 
9.5: Stopping use of cathinones 
 
As was the case with reasons for initiating and continuing consumption of synthetic cathinones, so 
with stopping use of them, in terms of drawing a distinction between motivations and reasons for doing 
so. Here again, the possibility of overlap and reinforcement does exist. 
 
Dealing first with motivations, tolerance, dependence and withdrawal symptoms have been reported 
by many synthetic cathinone users. However, there is little published information to date on tolerance, 
craving, dependence/addiction and withdrawal in respect of these aspects (Prosser and Nelson, 
2012). Ross and Peselow (2009) suggested that  “the dopaminergic stimulation of the reward system 
could explain the development” of these consequences. These factors can create difficulties in 
ceasing cathinone use. In respect of mephedrone, users have reported tolerance, craving (being 
‘moreish’), need to re-dose, loss of control, addiction and stimulant withdrawal syndrome; echoing 
those found amongst amphetamine and cocaine dependent individuals (Bajaj et al., 2010; Carhart-
Harris et al., 2011; Dargan et al., 2010; EMCDDA, 2011; Reed, 2010; Winstock et al., 2011b; 
Brookman et al., 2017). Evidence is lacking on these issues in respect of methylone (Karila et al., 
2016). For MDPV there is some limited animal evidence for some of these features (tolerance, 
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craving, dependence and withdrawal syndrome) (Coppola  and Mondola, 2012; Gannon et al., 2017). 
The structural parent of MDPV, α-PVP appears to give rise to extreme craving and risk of binge-
consumption (EMCDDA, 2016b).  
 
Unpleasant physical and mental symptoms may be experienced when going through withdrawal from 
synthetic cathinones. Feelings of depression and anxiety following use of mephedrone have been 
reported, but no physical withdrawal syndrome has been described (Dargan et al., 2011; Prosser and 
Nelson, 2012). Tiredness, insomnia, nasal congestion and impaired concentration have also been 
described as symptoms indicating mephedrone withdrawal (Winstock et al., 2011b). Pyschological 
dependency is possible in terms of mephedrone (Dargan et al., 2011). Following the abrupt stopping 
of chronic mephedrone, methcathinone and MDPV, some users have reported symptoms of anxiety 
and depression, craving, anhedonia, anergia and insomnia (Centers for Disease Control and 
Prevention (CDC), 2011; Winstock et al., 2011a). 
 
Whilst Van Hout (2014) notes that 4-MEC users did not report withdrawal symptoms akin to those of 
mephedrone (i.e. depression, anergia, anhedonia, or insomnia), there is a case-report of neonatal 
withdrawal syndrome in a baby whose mother was a chronic 4-MEC user “The newborn presented 
with increased jitteriness and irritability, highpitched cry, hypertonia in the limbs and brisk tendon 
reflexes” (Pichini et al., 2014).  
 
In terms of treatment for cathinone withdrawal, bupropion has been suggested (Coppola and Mondola, 
2012; Lev-Ran, 2012). 
 
Other motivations for cessation of use may include: previously experienced health harms, including 
negative impacts on physical and mental well-being, e.g. personality change, as well as not liking 
consuming NPS (MacLeod et al., 2016), including cathinones. The most common adverse reactions 
due to cathinones use are restlessness and anxiety, ranging from mild agitation to severe psychosis. 
Furthermore, tachycardia, hypertension, abdominal pain, chills, flushing, sweating, hyperthermia, renal 
failure, rhabdomyolysis, and seizures can also be observed (Schifano et al., 2017).  
 
Reasons for discontinuing use can include social pressures, e.g. peer-pressure. Negative effects on 
relationships with family and friends could act as an incentive to change (Ashrafioun et al., 2016; 
Brookman and Bennett, 2017; Brookman et al., 2017). Additional experiences which may also 
influence change include: recognising that one has neglected responsibilities; missing school or work; 
feeling that use is a problem; realising that money spent on buying cathinones could have been used 
for other purposes; shame/embarrassment; avoidance by others (Ashrafioun et al., 2016). 
 
Additional economic factors that could influence reduced consumption of synthetic cathinones or even 
cessation of use are the corollaries of those influnces which helped push their use in 2009-11: 
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increased price, reduced availability or reduced quality of cathinones; increased availability and quality 
of amphetamines, cocaine and ecstasy/MDMA. 
 
Such external reasons or drivers such as those briefly outlined above are more lkely to be influenced 
by policy and treatment, thereby making individuals more receptive/susceptible to change. 
 
 
Reasons to stop cathinone use 
 
Major reasons for encouraging individuals to stop their use of synthetic cathinones include the 
potentially very serious physiological and psychiatric/psychological consequences that may occur.  
These, as a result of chronic use of both natural and synthetic cathinones, can include: suicidal 
ideation, attempted suicide, as well as completed suicide; paranoia, including audio and visual 
hallucinations; psychoses; depression; mood disturbances; sleep deprivation; loss of appetite leading 
to rapid weight-loss (Brookman et al., 2017).  
 
Other reasons to stop can include: the avoidance of acquisitive crime to fund use; fear of acquiring a 
criminal record and/or being imprisoned; reducing the potential for violence when under the infuence; 
debt-avoidance; avoiding loss of employment and/or being made homeless (Brookman et al., 2017; 
Brookman and Bennett, 2017). 
 
 
Injecting behaviours and blood-borne infections 
 
The injecting of NPS is of increasing concern in Europe, the USA and elsewhere. There are several 
aspects to this issue, which will be briefly described, as the consequences of injecting synthetic 
cathinones can be very serious and injectors/users need to be aware of/educated about these in the 
hope that they will make rational decisions in relation to these risks. 
 
Injecting drugs, especially powders or crushed pills (the commonest form  of synthetic cathinones) 
diluted in a liquid, can cause damage to the injection sites, venous system and cause blockages such 
as thrombi – with associated risks of death. Injecting stimulant users are likely to inject more frequently 
due to their relatively short length of action, and share contaminated injecting equipment, thereby 
increasing health risks (Fischer et al., 2013; UNODC, 2017a). 
 
At-risk populations include subgroups of Men having sex with Men (MSM), “long-term abstinent former 
opiate users, people who inject other drugs such as heroin and amphetamines, people who switch to 
injecting synthetic cathinones and people who have switched from snorting to injecting” (UNODC, 
2017a). Such changes have occurred in Hungary during 2011-5 (Tarján et al., 2017). Typical synthetic 
cathinones injected by PWID in Hungary changed over time: 2010 mephedrone; 2011 MDPV and 4-
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MEC; 2012-3 pentedrone; 2014 α-PVP; 2015 α-PHP (Rácz et al., 2015; Péterfi et al., 2014; Hungarian 
Focal Point, 2015). 
  
Within the Chemsex context in the UK, synthetic cathinones/mephedrone misuse, either on their own 
or together with methamphetamine and/or GHB/GBL, especially in the MSM sub-population, has been 
associated with unprotected sex practices, sharing syringes, and highly elevated risk of the spread of 
blood-borne and sexually transmitted diseases including HIV and hepatitis C (Bourne et al., 2014, 
2015; UNODC, 2017a). HIV rates amongst synthetic cathinone injectors appear to be higher than in 
‘traditional’ drug injecting populations, e.g. Mephedrone, MDPV and methylone injectors in San Diego, 
California  (Wagner et al., 2014), in Ireland amongst homeless α-PVP injectors who often reused 
syringes and shared filters (Giese et al., 2015); English mephedrone injectors (PHE, 2015); and 
pentedrone injectors in Hungary (Rácz et al., 2016). 
 
 
Morbidity and mortality 
 
A detailed description of the adverse medical consequences, including death, resulting from the use of 
synthetic cathinones is outside the scope of this chapter. However, it is important for (would-be) users 
of such molecules to be aware of the potential risks to which they may expose themselves. This may 
influence their decisions to use in the first place, make changes in their practice(s), or even stop. 
 
 
Intoxications, hospital admissions 
 
Cathinones are also characterised with increased presentations to emergency departments for both 
physical and mental health associated toxicity (UNODC, 2017a). For example, during 2011 there were 
22,904 visits to US Emergency Departments (ED) recorded by the Drug Abuse Warning Network 
(DAWN) as caused by bath salts. This represented about 0.9% of all ED visits. One-third of cases 
involved solely bath salts, 15% were implicated with natural cannabis or synthetic cannabinoids, and 
52% with combinations of other drugs (DAWN, 2013). In Florida between September 2014 and 
December 2015 an outbreak of α-PVP use was associated with 80 deaths and thousands of ED 
admissions, many from excited delirium syndrome - hyperstimulation, paranoia and hallucinations that 
can lead to violent aggression and self-injury (NDEWS, 2016). 
 
The Euro-DEN project compiled information on 10,709 ED admissions across 16 centres in 10 
European cities for the period 2014-5. NPS accounted for 7.3% of admissions; of which 61.2% were 
cathinones (mephedrone 73.9% of these). There were 9 deaths related to NPS out of a total of 67: all 
of these involved cathinones (Dargan, 2017).  
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A retrospective study conducted in Germany over a 6-year period between January 2010 and January 
2016 on cathinone self-reported users presenting to emergency departments due to cathinone-related 
complications revealed that 64 % of patients (n = 81) were males with a median age of 34 years 
(Romanek et al., 2017). In this study, cathinones which related to higher rates of intoxications were 
MDPV, methylone and 3-MMC, in reducing order of frequency (Romanek et al., 2017). 
 
 
Fatalities 
 
A range of synthetic cathinones (including mephedrone, methylone and butylone, ethylone, α-PVP, 
MDPV, and methedrone) has been associated with fatalities (Schifano et al., 2017). This is especially 
true in the UK, where the number of synthetic cathinone-related poisoning deaths rose from 6 in 2010 
to a peak of 49 in 2015, falling to 25 in 2016, with a cumulative total of 157. The majority (122) of 
these involved mephedrone (ONS, 2015, 2016a, 2016b, 2016c, 2017a, 2017b). In Scotland, the 
number of cathinone deaths registered rose from 1 in 2009 to 8 in 2010, falling to 6 in 2014 and 2015, 
and down to 1 in 2016, with a cumulative total of 32. The majority (17) of these involved mephedrone 
(NRS, 2017). In Northern Ireland, the number of cathinone deaths registered rose risen from 1 in 2010 
to 3 before falling to 1 in 2016, with a cumulative total of 27. Only 6 of these involved mephedrone 
(NISRA, 2016; and personal communication to lead author for provisional 2016 data). In summary, 
since 2009 the cumulative total of synthetic cathinone-related poisoning deaths registered in the UK 
by the end of 2016 was 216, of which 145 involved mephedrone. 
 
In a three-year review of NPS detected in 203 in-life or post-mortem blood and urine and in UK 
criminal case works, mephedrone and 4-MEC were the most common NPS identified. Interestingly, all 
fatalities related to cathinones in this review were hangings and mechanical suicides (Elliott & Evans, 
2014). Another 3-year review conducted in Poland, from 2012-2014, for 112 cases, where NPS were 
identified in biological material from people driving under the influence of drugs, cathinones were 
prevalent in 88 % of the cases. In decreasing frequency, these were: 3-MMC, α-
pyrrolidinopentiophenone (α-PVP), pentedrone, 3',4'-methylenedioxy-α-pyrrolidinobutyrophenone 
(MDPBP), ethcathinone, mephedrone, methylene- dioxypyrovalerone (MDPV), 4-methylethcathinone 
(4-MEC), buphedrone and methylone (Adamowicz et al., 2016). 
 
 
9.6: What challenges might the future hold? 
 
The different constituencies dealing with NPS are likely to continue facing challenges which may 
further compound the problem of getting a comprehensive understanding of synthetic cathinones.  
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Further new synthetic cathinone molecules are likely to appear, leading to not only intoxications but 
also to psychoses, paranoia and other psychiatric issues. Deaths are also likely to continue, especially 
against a background of polysubstance consumption. 
 
There are reports of ’vaping’ equipment being used to administer NPS/’legal highs’ (Jones, 2016; 
Thurtle et al., 2017). There is some evidence of this occurring with mexedrone (Roberts et al., 2017), 
so it is conceivable that users of other cathinones could experiment with such a method of 
administration. 
   
Following the introduction of ‘blanket ban’ legislation in countries such as Ireland and the UK, and 
disappearance of ‘smart’ or ‘head’ shops, it is likely that the Web (Surface and Deep) will increasingly 
utlised to source supplies of synthetic cathinones. NPS now being traded alongside traditional ‘street’ 
drugs such heroin, cocaine and cannabis in clandestine street drug markets (Shapiro and Daly, 2017).  
 
 
9.7: Conclusions 
 
This chapter has looked at the current and emerging knowledge and challenges of synthetic 
cathinones from epidemiological, anthropological and clinical pharmacological perspectives. With so 
much remaining unknown about a wide range of issues concerned with NPS, including synthetic 
cathinones, the need for inter-disciplinary approaches to the ever-evolving NPS phenomenon is clearly 
demonstrable. The need for timely, up to date information and the development of methods to 
understand the potential characteristics and properties of new molecules still remains. Forensic as well 
as socio-anthropological approaches are required to have a deeper understanding of synthetic 
cathinones and the implications of their use. This will help policy-makers, educationalists, health and 
other professionals, service providers and funders to develop responses including prevention and 
intervention initiatives. Furthermore, (would-be) psychoactive substance users can be assisted in 
making more rational decisions about synthetic cathinones. 
 
The key dimensions that need documenting are the human ones of why people are looking for new 
synthetic cathinones, amongst other available NPS, what effects they are seeking, what they are 
actually taking (how, where and when), and what the consequences of their actions may be. 
Furthermore, external influences or factors which could may play a causative role in how these play 
out also need to be understood. The use of historic or traditional methods of epidemiology can play a 
part, but new and innovative approaches need to be continually improved and developed in a world of 
increasing reliance on rapid electronic exchange and dissemination of information.  
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